| Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease J Wagner, S Ryazanov, A Leonov, J Levin, S Shi, F Schmidt, C Prix, ... Acta neuropathologica 125, 795-813, 2013 | 463 | 2013 |
| Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model NW Schiffer, SA Broadley, T Hirschberger, P Tavan, HA Kretzschmar, ... Journal of Biological Chemistry 282 (12), 9195-9203, 2007 | 132 | 2007 |
| Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets U Bertsch, KF Winklhofer, T Hirschberger, J Bieschke, P Weber, FU Hartl, ... Journal of virology 79 (12), 7785-7791, 2005 | 114 | 2005 |
| Structural instability of the prion protein upon M205S/R mutations revealed by molecular dynamics simulations T Hirschberger, M Stork, B Schropp, KF Winklhofer, J Tatzelt, P Tavan Biophysical journal 90 (11), 3908-3918, 2006 | 57 | 2006 |
| Extracting Markov models of peptide conformational dynamics from simulation data V Schultheis, T Hirschberger, H Carstens, P Tavan Journal of Chemical Theory and Computation 1 (4), 515-526, 2005 | 56 | 2005 |
| From High‐Throughput Cell Culture Screening to Mouse Model: Identification of New Inhibitor Classes against Prion Disease M Geissen, F Leidel, M Eiden, T Hirschberger, C Fast, U Bertsch, P Tavan, ... ChemMedChem 6 (10), 1928-1937, 2011 | 27 | 2011 |
| New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases A Giese, U Bertsch, H Kretzschmar, M Habeck, T Hirschberger, P Tavan, ... US Patent App. 12/996,833, 2011 | 17 | 2011 |
| Diphenylpyrazole-derived compounds increase survival time of mice after prion infection F Leidel, M Eiden, M Geissen, HA Kretzschmar, A Giese, T Hirschberger, ... Antimicrobial agents and chemotherapy 55 (10), 4774-4781, 2011 | 16 | 2011 |
| Piperazine derivatives inhibit PrP/PrPres propagation in vitro and in vivo F Leidel, M Eiden, M Geissen, T Hirschberger, P Tavan, A Giese, ... Biochemical and Biophysical Research Communications 445 (1), 23-29, 2014 | 9 | 2014 |
| Causal therapy of Parkinson's disease with anle138b, a novel protein aggregation inhibitor. J Levin, J Wagner, S Ryazanov, A Leonov, S Shi, F Schmidt, C Prix, ... 15th International Congress of Parkinsons Disease and Movement Disorders …, 2011 | 4 | 2011 |
| Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift) U Bertsch, A Giese, H Kretzschmar, P Tavan, T Hirschberger, J Bieschke, ... US Patent App. 11/597,672, 2010 | 4 | 2010 |
| Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases A Giese, U Bertsch, H Kretzschmar, M Habeck, T Hirschberger, P Tavan, ... US Patent 10,435,373, 2019 | 1 | 2019 |
| Entwicklung von Medikamenten gegen Prionkrankheiten T Hirschberger lmu, 2007 | 1 | 2007 |
| Single molecule analysis of protein aggregation and prions by SIFT U Bertsch, KF Winklhofer, T Hirschberger, J Bieschke, P Weber, FU Hartl, ... FEBS Journal 272 (Suppl. Suppl. 1), 338-339, 2005 | 1 | 2005 |
| Single molecule analysis of protein aggregation and prions by sift HA Kretzschmar, U Bertsch, KF Winklhofer, T Hirschberger, J Bieschke, ... Journal of Neuropathology and Experimental Neurology 64 (5), 441-441, 2005 | 1 | 2005 |
| Identification of anti-prion drugs by high-throughput screening based on sift U Bertsch, A Giese, H Kretzschmar, P Tavan, T Hirschberger, J Bieschke, ... | | 2005 |
